Valuation: Genix Pharmaceuticals Corporation

Market Cap 918K 658K 589K 542K 491K 62.5M 936K 6.47M 2.6M 32.87M 2.47M 2.42M 104M P/E 2024
-40.5x
P/E 2025 -5.33x
Enterprise Value 1.92M 1.37M 1.23M 1.13M 1.03M 130M 1.95M 13.5M 5.42M 68.65M 5.16M 5.05M 216M EV / Sales 2024
929,496,174x
EV / Sales 2025 -
Free-Float
53.08%
Yield 2024 *
-
Yield 2025 -
1 day-25.00%
1 week-25.00%
Current month-25.00%
1 month-25.00%
6 months-25.00%
Current year-40.00%
1 week 0.02
Extreme 0.015
0.02
1 month 0.02
Extreme 0.015
0.02
Current year 0.02
Extreme 0.015
0.02
1 year 0.02
Extreme 0.015
0.03
3 years 0.02
Extreme 0.015
0.09
5 years 0.02
Extreme 0.015
0.19
10 years 0.01
Extreme 0.01
0.3
Manager TitleAgeSince
Chief Executive Officer 57 2018-08-02
Director of Finance/CFO - 2026-05-03
President - 2021-05-20
Director TitleAgeSince
Director/Board Member 57 2018-08-02
Director/Board Member 76 2019-03-10
Director/Board Member 48 2019-09-04
Date Insider Type Main position Quantity % Market Cap. Importance
9/9/25 Option

Chairman

1,000,000 1.6885%
9/9/25 Option

Chairman

1,000,000 1.6885%
9/9/25 Option

Chief Executive Officer

1,000,000 1.6885%
Change 5-day change 1-year change 3-year change Capi.($)
-25.00%-25.00%-50.00%-62.50% 658K
+3.19%+11.31%+67.86%+150.58% 1,263B
-0.73%+3.56%+44.51%+85.81% 658B
+1.41%+3.24%+29.22%+107.83% 521B
+0.42%+3.20%+54.15%+67.18% 391B
+2.18%+2.93%+73.30%+45.62% 369B
+1.12%+4.52%+35.30%+58.08% 307B
+6.96%+8.86%+11.27%+36.62% 290B
+1.15%+6.09%+59.59%+77.06% 252B
+3.06%+9.38%+44.11%+119.47% 212B
Average -0.94%+5.31%+36.93%+68.57% 426.19B
Weighted average by Cap. +1.19%+6.60%+50.88%+98.31%

Financials

2024 2025
Net sales 0 0 0 0 0 0.28 0 0.03 0.01 0.15 0.01 0.01 0.46 -
Net income -73.2K -52.46K -46.98K -43.22K -39.16K -4.98M -74.57K -515K -207K -2.62M -197K -193K -8.26M -335K -240K -215K -198K -179K -22.8M -341K -2.36M -947K -11.99M -901K -882K -37.82M
Net Debt 804K 576K 516K 475K 430K 54.73M 819K 5.66M 2.27M 28.79M 2.16M 2.12M 90.78M 999K 716K 641K 590K 535K 68M 1.02M 7.04M 2.82M 35.77M 2.69M 2.63M 113M
Projected Income Statement - Annual - Genix Pharmaceuticals Corporation
Logo Genix Pharmaceuticals Corporation
Genix Pharmaceuticals Corporation is a Canadian ophthalmic drugs company. The Company is a formulator, manufacturer, licensor and marketer of life sciences-related products with a focus on nutraceuticals and pharmaceuticals. Its operations consist primarily of the research, development, manufacture, in-licensing and sales of novel and healthcare products, focusing on proprietary over the counter (OTC) nutraceuticals and generic pharmaceuticals. The Company has been marketing and selling other nutraceuticals and some pharmaceutical products, such as bee propolis capsules, calcium liquid softgels, seal oil softgels, marine lipid softgels, Lecithin softgels, fish oil softgels, EPO softgels and spirulina powder. Its products include Ketorolac 0.5% Eye Drops, Timolol 0.5% Eye Drops, Diclofenac 0.1% Eye Drops, Moxifloxacin Hydrochloride 0.5% Eye Drops, Prednisolone Acetate 1% Eye Drops, Olopatadine 0.1% Eye Drops, and others.
Employees
4,000
Date Price Change Volume
  1. Stock Market
  2. Stocks
  3. GENX Stock